The possibilities of application of neutrophil gelatinase associated lipokalin and other markers of acute damage of kidneys under acute coronary syndrome


Cite item

Full Text

Abstract

The article considers application of markers of acute damage of kidneys (cystatin C, molecule of kidney damage-1, interleukin 18 and protein binding hepatic fatty acids of L-type) and most perspective of them - neutrophil gelatinase associated lipocalin (NGAL) in cardiology and in particular under acute coronary syndrome. Among markers of acute damage of kidneys specific attention was paid NGAL (in blood and urine). Its participation in pathogenesis of cardiovascular diseases is marked. The results of application of NGAL under different forms of ischemic heart disease, acute cardiac insufficiency, in cardiac-surgical patients are presented. The advantages of NGAL in comparison with markers of acute damage of kidneys mentioned above are demonstrated. At the same time, it is marked that there is not enough data testifying prognostic value of NGAL under acute coronary syndrome. There is not enough information about its comparison and interaction with natriuretic peptides.

About the authors

Maria A. Shalenkova

The municipal clinical hospital № 38

Email: mshalenkova@yandex.ru
MD PhD, consultant 603000 Nizhnii Novgorod, Russia

Z. D Mikhailova

The municipal clinical hospital № 38

603000 Nizhnii Novgorod, Russia

P. F Klimkin

The municipal clinical hospital № 38

603000 Nizhnii Novgorod, Russia

References

  1. Оганов Р.Г., Масленникова Г.Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения. Кардиоваскулярная терапия и профилактика. 2012; 11(1): 5-10.
  2. Концевая А.В., Калинина А.М., Колтунов И.Е., Оганов Р.Г. Социально-экономический ущерб от острого коронарного синдрома в России. Новости кардиологии. 2013; 4: 10-2.
  3. Soni S., Fahuan Y., Ronco C., Cruz D.N. Cardiorenal syndrome: biomarkers linking kidney damage with heart failure. Biomarkers Med. 2009; 3 (5): 549-60.
  4. Ronco C., McCullough P., Anker S., Anand I., Aspromonte N., Bagshaw S.M. et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality I nitiative. Eur. Heart J. 2010; 31: 703-11.
  5. Cruz D.N., Ricci Z., Ronco C. Clinical review: RIFLE and AKIN-time for reappraisal. Crit. Care. 2009; 13 (3): 211.
  6. Marenzi G., Assanelli E., Campodonico J., De Metrio M., Lauri G., Marana I. et al. Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit. Care Med. 2010; 38 (2): 438-44.
  7. Murugan R., Kellum J.A. Acute kidney injury: what's the prognosis? Nat. Rev. Nephrol. 2011; 7(4): 209-17.
  8. Park M.Y., Choi S.J., Kim J.K., Hwang S.D., Lee Y.W. Urinary cystatin C levels as a diagnostic and prognostic biomarker in patients with acute kidney injury. Nephrology (Carlton). 2013; 18 (4): 256-62.
  9. Torregrosa I., Montoliu C., Urios A., Elmlili N., Puchades M.J., Solis M.A. et al. Early biomarkers of acute kidney failure after heart angiography or heart surgery in patients with acute coronary syndrome or acute heart failure. Nefrologia. 2012; 32 (1): 44-52.
  10. Sun T.W., Xu Q.Y., Yao H.M., Zhang X.J., Wu Q., Zhang J.Y. et al. The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. Heart Lung. 2012; 41 (5): 456-62.
  11. Liang X.L., Liu S.X., Chen Y.H., Yan L.J., Li H., Xuan H.J. et al. Combination of urinary kidney injury molecule-1 and interleukin-18 as early biomarker for thediagnosis and progressive assessment of acute kidney injury following cardiopulmonary bypass surgery: a prospective nested case-control study. Biomarkers. 2010; 15 (4): 332-9.
  12. Luo Q., Zhou F., Dong H., Wu L., Chai L., Lan K. et al. Implication of combined urinary biomarkers in early diagnosis of acute kidney injury following percutaneous coronary intervention. Clin. Nephrol. 2013; 79 (2): 85-92.
  13. Huang Y., Don-Wauchope A.C. The clinical utility of kidney injury molecule 1 in the prediction, diagnosis and prognosis of acutekidney injury: a systematic review. Inflamm. Allergy Drug Targets. 2011; 10 (4) : 260-71.
  14. Parikh C.R., Abraham E., Ancukiewicz M., Edelstein C.L. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J. Am. Soc. Nephrol. 2005; 16 (10): 3046-52.
  15. Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr. Opin. Pediatr. 2011; 23 (2): 194-200.
  16. Doi K., Noiri E., Maeda-Mamiya R., Ishii T., Negishi K., Hamasaki Y. et al. Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit. Care Med. 2010; 38 (10): 2037-42.
  17. Katagiri D., Doi K., Honda K., Negishi K., Fujita T., Hisagi M. et al. Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann. Thorac. Surg. 2012; 93 (2): 577-83.
  18. Bennett M., Dent C.L., Ma Q., Dastrala S., Grenier F., Workman R. et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin. J. Am. Soc. Nephrol. 2008; 3 (3): 665-73.
  19. Haase M., Bellomo R., Devarajan P., Schlattmann P., Haase-Fielitz A. Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 2009; 54 (6): 1012-24.
  20. Haase M., Devarajan P., Haase-Fielitz A., Bellomo R., Cruz D.N., Wagener G. et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J. Am. Coll. Cardiol. 2011; 57 (17): 1752-61.
  21. Helmersson-Karlqvist J., Larsson A., Carlsson A.C., Venge P., Sundstrom J., Ingelsson E. et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with mortality in a community-based cohort of older Swedish men. Atherosclerosis. 2013; 227 (2): 408-13.
  22. Kafkas N., Demponeras C., Zoubouloglou F., Spanou L., Babalis D., Makris K. Serum levels of gelatinase associated lipocalin as indicator of the inflammatory status in coronary artery disease. Int. J. Inflam. 2012; 2012: 189797.
  23. Macdonald S., Arendts G., Nagree Y., Xu X.F. Neutrophil Gelatinase-Associated Lipocalin (NGAL) predicts renal injury in acute decompensated cardiac failure: a prospective observational study. BMC Cardiovasc. Disord. 2012; 12: 8.
  24. Cruz D.N., Gaiao S., Maisel A., Ronco C., Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin. Chem. Lab. Med. 2012; 50 (9): 1533-45.
  25. Daniels L.B., Barrett-Connor E., Clopton P., Laughlin G.A., Ix J.H., Maisel A.S. Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study. J. Am. Coll. Cardiol. 2012; 59 (12): 1101-9.
  26. Sahinarslan A., Kocaman S.A., Bas D., Akyel A., Ercin U., Zengin O. et al. Plasma neutrophil gelatinase-associated lipocalin levels in acute myocardial infarction and stable coronary artery disease. Coron Artery Dis. 2011; 22 (5): 333-8.
  27. Akcay A.B., Ozlu M.F., Sen N., Cay S., Ozturk O.H., Yalcn F. et al. Prognostic significance of neutrophil gelatinase-associated lipocalin in ST-segment elevation myocardial infarction. J. Investig. Med. 2012; 60 (2): 508-13.
  28. Pinelli A., Trivulzio S., Rossoni G., Redaelli R., Brenna S. Factors involved in sudden coagulation observed in patients with acute myocardial infarction. In Vivo. 2012; 26 (6): 1021-5.
  29. Helanova K., Parenica J., Dlouhy V., Pavkova Goldbergova M., Cermakova Z., Gottwaldova J. et al. The importance of NGAL and cystatin C biomarkers in cardiovascular diseases. Vnitr. Lek. 2012; 58 (4): 286-90.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies